Help paying · Medicare negotiated price · pharmacy cost · cycle 2028
Verzenio (abemaciclib): where help paying exists, where Medicare's negotiation stands and what pharmacies pay
1 assistance program lists abemaciclib, each with its income ceiling and when we read it. CMS has selected Verzenio for the 2028 negotiation cycle. The CMS file we read (November 6, 2026) lists its negotiated price as taking effect January 1, 2028 and holds no price for it yet, so this page shows no negotiated price. 2 non-manufacturing label changes are dated in the last 12 months in the FDA's file. ClinicalTrials.gov lists 88 recruiting trials that name abemaciclib.
Every package CMS lists
Packages the CMS file lists for Verzenio, with NADAC per unit where the benchmark has one (per unit, as the files state).
| NDC | Unit | CMS price status | NADAC |
|---|---|---|---|
| 00002-4483-54 | n/a | Selected; price takes effect January 1, 2028, not yet published | n/a |
| 00002-4815-54 | n/a | Selected; price takes effect January 1, 2028, not yet published | n/a |
| 00002-4815-62 | n/a | Selected; price takes effect January 1, 2028, not yet published | n/a |
| 00002-5337-54 | n/a | Selected; price takes effect January 1, 2028, not yet published | n/a |
| 00002-6216-54 | n/a | Selected; price takes effect January 1, 2028, not yet published | n/a |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA208716 | Verzenio | September 28, 2031 | none listed | September 28, 2031 | patent 7855211; 4 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Verzenio of $1.06 billion in 2024, across 71,933 claims and 11,239 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $1.06 billion | 71,933 | 11,239 | $14,691 |
| 2023 | $756.85 million | 50,481 | 8,217 | $14,993 |
| 2022 | $474.17 million | 33,805 | 6,042 | $14,027 |
| 2021 | $324.57 million | 24,509 | 4,406 | $13,243 |
| 2020 | $286.19 million | 22,862 | 4,118 | $12,518 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 8 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| NV | 321 | $4,409,455 | Fee-for-service only |
| KY | 127 | $1,624,972 | All record types |
| WI | 97 | $1,474,879 | All record types |
| FL | 97 | $1,380,895 | Fee-for-service only |
| AL | 67 | $1,013,657 | All record types |
| OK | 62 | $1,011,196 | Fee-for-service only |
| NM | 63 | $948,257 | All record types |
| CA | 48 | $799,779 | All record types |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (4 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 90 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
Programs in our finder that list abemaciclib. Each shows its income ceiling, when we read it and whether we checked it against the program's own document. Eligibility is decided by the program, not by us.
- Lilly Cares Foundation manufacturer
Income at or below 300%, 400% or 500% FPL depending on the Lilly Cares group of your medicine ($47,880, $63,840 or $79,800 for one person)
Ceiling read on the program's own document, November 6, 2026.
Check where your income sits against each ceiling: open the assistance finder. See what has changed and when we last verified each program on the program status board.
Label changes
FDA actions on the applications behind Verzenio dated since November 11, 2025, leaving out manufacturing (CMC) changes. 2 changes in the window.
| Date | Class | Application | Submissions | FDA documents |
|---|---|---|---|---|
| September 18, 2026 | Efficacy | NDA208716 | 22 | Label (PDF) posted September 22, 2026FDA letter posted September 22, 2026 |
| July 13, 2026 | Efficacy | NDA208716 | 21 | Label (PDF) posted July 15, 2026FDA letter posted July 20, 2026 |
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Clinical trials recruiting
ClinicalTrials.gov lists 88 interventional trials that name abemaciclib and are recruiting, and 16 more not yet recruiting. By phase: Phase 2: 37, PHASE1/PHASE2: 22, Phase 1: 10, Phase 3: 8, Not applicable: 7, Phase 4: 2, Early phase 1: 2. The 10 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT06169371 | Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)Breast Cancer | Phase 4 | University of Illinois Chicago | November 6, 2026 | United States |
| NCT03424005 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerMetastatic Breast Cancer | Phase 1 / Phase 2 | Hoffmann-La Roche | November 6, 2026 | United States, Australia, France and 6 more |
| NCT07214532 | Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerBreast Neoplasms; Carcinoma, Ductal, Breast; Receptors, Estrogen (for ER-positive Requirement) | Not applicable | Natera, Inc. | November 5, 2026 | United States |
| NCT04633239 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerRecurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 1 | National Cancer Institute (NCI) | November 4, 2026 | United States |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Breast Neoplasms; Neoplasm Metastasis | Phase 3 | Eli Lilly and Company | November 4, 2026 | United States, Argentina, Australia and 7 more |
| NCT07521202 | IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCEHR+/HER2- Early Breast Cancer | Not applicable | Institut fuer Frauengesundheit | November 4, 2026 | Germany |
| NCT07114601 | A Study of LY4257496 in Participants With Cancer (OMNIRAY)Breast Neoplasms; Colorectal Neoplasms; Prostate Neoplasm | Phase 1 | Eli Lilly and Company | November 4, 2026 | United States, Canada, China and 4 more |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasIntracranial Meningioma; Recurrent Meningioma; NF2 Gene Mutation | Phase 2 | Alliance for Clinical Trials in Oncology | November 3, 2026 | United States |
| NCT04802759 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerInoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | Phase 1 / Phase 2 | Hoffmann-La Roche | November 3, 2026 | United States, Australia, Israel and 2 more |
| NCT07112053 | A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast CancerAnatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma | Phase 2 | University of Washington | November 2, 2026 | United States |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Verzenio?
CMS has selected Verzenio for the 2028 negotiation cycle. The CMS file we read (November 6, 2026) lists its negotiated price as taking effect January 1, 2028 and holds no price for it yet, so this page shows no negotiated price. When CMS publishes a price it will be a Medicare Part D price agreed with the manufacturer, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
No negotiated price is published yet, so there is nothing to compare with the pharmacy acquisition benchmark.
Is there help paying for Verzenio?
1 assistance program lists it in our finder. Eligibility depends on income, coverage and the program's current rules; each program's own page decides.
When could a generic version of Verzenio arrive?
For Verzenio, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA208716, September 28, 2031. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Verzenio?
ClinicalTrials.gov lists 88 recruiting interventional trials that name abemaciclib (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Verzenio?
CMS's Medicare Part D spending dataset reports gross spending on Verzenio of $1.06 billion in 2024, across 71,933 claims and 11,239 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/verzenio.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.